Research
-
Glaucoma drug studied to prevent lung Infection in COVID-19 patients
Vanderbilt University Medical Center is evaluating razuprotafib, a drug used to treat glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. Read MoreJun 24, 2020
-
A connection to schizophrenia
The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found. Read MoreJun 23, 2020
-
Single mutation causes seizure disorder
A single mutation in one gene can impair inhibitory signaling in the brain and cause multiple types of seizures and behavioral abnormalities. Read MoreJun 22, 2020
-
Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19
The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. Read MoreJun 21, 2020
-
Probing DNA damage repair
After discovering a new mechanism for DNA damage repair last year, Vanderbilt biochemists now provide direct evidence for how it works. Read MoreJun 18, 2020
-
Studying cells in reduced dimensions
Vanderbilt cell biologists have developed an unbiased, quantitative framework for evaluating single-cell data. Read MoreJun 18, 2020
-
All of Us program launches cloud-based research platform
On May 27, the All of Us Research Program launched the beta version of its cloud-based research platform, the Researcher Workbench. Read MoreJun 18, 2020
-
$3.3 million project aims to transform grid management with risk metrics for renewables
The goal of the project—Risk-Aware Market Clearing—is a blueprint for an end-to-end, data-driven approach that balances cost and minimizes system-level risk. Market clearing is the process that keeps the supply level to the demand with no leftover of either. Read MoreJun 17, 2020
-
Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders
Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read MoreJun 16, 2020
-
Engineers advance insights on black phosphorus as a material for future ultra-low power flexible electronics
Black phosphorus is a crystalline material that is attracting growing research interest from semiconductor device engineers, chemists and material scientists to create high-quality atomically thin films. Read MoreJun 16, 2020
-
Robotic technology speeds arrhythmia gene classification
Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions. Read MoreJun 12, 2020
-
C.diff captures blood cell cofactor to build defensive shield
Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics. Read MoreJun 10, 2020
-
Vanderbilt, AstraZeneca sign new COVID-19 antibody agreement
After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read MoreJun 9, 2020
-
Staph’s activation of blood clotting
Staph bacteria may change the factor they use to activate blood clotting — to evade the immune response — a new study suggests. Read MoreJun 9, 2020
-
Protecting the injured kidney
Leslie Gewin and colleagues have upended conventional dogma about Wnt/beta-catenin signaling in the kidney, finding that it protects against chronic kidney disease rather than promoting it. Read MoreJun 4, 2020
-
Potential new cancer target
Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis. Read MoreJun 4, 2020
-
Remdesivir helps reduce COVID-19 recovery time: study
The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine. Read MoreJun 4, 2020
-
VUMC research ramps up in COVID-19 transition
As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center. Read MoreMay 21, 2020
-
Team uses imaging to study ways the heart is affected by coronavirus
Researchers are using imaging and diagnostic pathology to examine postmortem hearts donated by victims of COVID-19 to gain a better understanding of how the coronavirus that causes COVID-19 affects the heart. Read MoreMay 21, 2020
-
VUMC Research Enterprise begins ramping up
As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center. Read MoreMay 19, 2020